Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: lyell.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $45.00 | Neutral → Buy | H.C. Wainwright |
| 10/30/2024 | $6.00 → $1.00 | Buy → Underperform | BofA Securities |
| 6/27/2024 | $6.00 → $1.00 | Buy → Neutral | H.C. Wainwright |
| 8/28/2023 | $15.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 11/14/2022 | $15.00 → $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/11/2022 | $13.00 → $7.00 | Buy → Neutral | Goldman |
| 10/17/2022 | $12.00 | Buy | H.C. Wainwright |
| 1/6/2022 | $25.00 → $20.00 | Overweight | Morgan Stanley |
| 7/12/2021 | $25.00 | Buy | BofA Securities |
| 7/12/2021 | $25.00 | Overweight | Morgan Stanley |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
S-3 - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
SCHEDULE 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SCHEDULE 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SCHEDULE 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
10-Q - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright upgraded Lyell Immunopharma from Neutral to Buy and set a new price target of $45.00
BofA Securities downgraded Lyell Immunopharma from Buy to Underperform and set a new price target of $1.00 from $6.00 previously
H.C. Wainwright downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $1.00 from $6.00 previously
JP Morgan downgraded Lyell Immunopharma from Overweight to Neutral and set a new price target of $5.00 from $15.00 previously
Morgan Stanley downgraded Lyell Immunopharma from Overweight to Equal-Weight and set a new price target of $7.00 from $15.00 previously
Goldman downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $7.00 from $13.00 previously
H.C. Wainwright initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $12.00
Morgan Stanley reiterated coverage of Lyell Immunopharma with a rating of Overweight and set a new price target of $20.00 from $25.00 previously
BofA Securities initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $25.00
Morgan Stanley initiated coverage of Lyell Immunopharma with a rating of Overweight and set a new price target of $25.00
Fastest customizable press release news feed in the world
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of California, Los Angel
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer in an ongoing U.S. Phase 1 clinical trialReceived RMAT designation from the U.S. FDA for ronde-cel for the treatment of patients with relapsed or refractory LBCL receiving treatment in the second-line (2L) settingAnnounced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of ronde‑cel for the treatment of aggressive large B-cell lymphoma have
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killingLyell management will host an investor webcast at 8:30 AM ET today SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Ronde-cel is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate, currently in pivotal development for the treatment o
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lyell's next-generation, dual-targeting CD19/CD20 CAR T-cell therapy designed to deliver improved complete response rates and longer duration of responses over currently approved CD19 CAR T-cell therapiesSteering Committee of distinguished lymphoma experts established to advise on the design and conduct of this first-of-its-kind CAR T-cell clinical trial SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (N
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8th at 9:15 am Eastern TimeH.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10th at 8:00 am Eastern Time A live webcast of the presentation can be accessed through the Investors section of the Company's website at
Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in the third‑ or later-line (3L+) setting; remain on track to initiate a pivotal trial in the second-line (2L) setting by early 2026Entered into a securities purchase agreement for a private placement for gross proceeds of up to approximately $100 millionPro-forma cash of approximately $347 million inclusive of the initial proceeds from the private placement to support advancing pipeline into mid-2027 through ke
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximately $100 million. The initial closing of approximately $50 million of common stock at a price of $13.32 per share is anticipated to occur on or about July 25, 2025, subject to customary closing conditions. The Company has the right, but not the obligation, to require the investors to purchase approxi
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright "HCW@Home" Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET. The discussion will highlight the positive new clinical data recently presented in an oral session at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on LYL314, Lyell's lead product candidate, and the emerging landscape of next-generation dual targeting chimeric antigen
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with large B-cell lymphoma treated in the third- or later-line settingLyell to host an investor webcast at 8:00 AM ET today SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunoph
Live Leadership Updates
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate
Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023. "Lyell continues
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary. "Matt is an experienced company builder who has successfully led growth in compl
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the company's board and former president and chief executive officer (CEO) of Myovant Sciences, has been named Lyell's president & CEO effective today. Dr. Seely succeeds Ms. Liz Homans following a four-year tenure as president and then CEO. Ms. Homans will remain a consultant to the company through June 2024. Dr. Seely has extensive biopharmaceutical leadership experience with a track record of success building companies
Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical developmentCash, cash equivalents and marketable securities of $750.7 million as of September 30, 2022; extends funding into 2026 and supports advancement of multiple product candidates through key clinical milestones SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell) (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today provided business highlights and reported financial results for the third quarter of 2022. "In the past year we
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies. "Rahsaan's experience and expertise across corporate law and intellectual property make him an ideal fit for Lyell as we advance clinical development of multiple products in our pipeline targeting solid tumor cancers," said Liz Ho
Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipelineResearch highlighting novel reprogramming technologies designed to overcome barriers to successful adoptive cell therapy in solid tumors presented at multiple scientific conferences SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Lyell) (NASDAQ:LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today provided business highlights and reported financial results for the first quarter of 2022. "We continue to progress our mission to develop T-cell therapies tha
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ:LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A veteran biotech leader with more than a decade of experience heading translational cell and gene therapy programs, Dr. Lee will set and oversee the company's research strategy and advance its research pipeline. "We are thrilled to welcome Gary and his scientific expertise in translational cell therapy to the Lyell team," said Liz Homans, Chief Executive Officer of Lyell. "Beyond his exceptional scientifi
Live finance-specific insights
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of California, Los Angel
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killingLyell management will host an investor webcast at 8:30 AM ET today SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with large B-cell lymphoma treated in the third- or later-line settingLyell to host an investor webcast at 8:00 AM ET today SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunoph
Strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT's multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and is discontinuing development of LYL797, LYL845 and earlier-stage TIL programsCash runway following the close of the transaction is expected to fund operations into 2027, through impor
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohortsExpanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple
This live feed shows all institutional transactions in real time.
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)